Extending Aromatase-Inhibitor Adjuvant Therapy to 10

New England Journal of Medicine
375, 209-219
DOI: 10.1056/nejmoa1604700

Citation Report

#	Article	IF	Citations
1	Oncology providers’ perspectives on endocrine therapy prescribing and management. Patient Preference and Adherence, 2016, Volume 10, 2007-2019.	0.8	20
2	Estrogens - the Saviors of Cognitive Function?. Breast Care, 2016, 11, 238-239.	0.8	1
3	Recent advances in the medical treatment of breast cancer. F1000Research, 2016, 5, 2786.	0.8	10
4	How Do We Best Ensure That Rosebuds Are Gathered?. Journal of Oncology Practice, 2016, 12, 1157-1159.	2.5	0
5	Are another 5 years of adjuvant aromatase inhibitor therapy needed?. Breast Cancer: Targets and Therapy, 2016, Volume 8, 207-209.	1.0	0
6	Supportive care of women with breast cancer: key concerns and practical solutions. Medical Journal of Australia, 2016, 205, 471-475.	0.8	36
7	Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. Current Opinion in Oncology, 2016, 28, 455-460.	1.1	9
8	ASCO 2016: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 211-214.	0.3	4
10	Endocrine Therapy in Premenopausal Hormone Receptorâ€“Positive Breast Cancer. Journal of Oncology Practice, 2016, 12, 1148-1156.	2.5	7
11	Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumoursâ€”a review. Cancer and Metastasis Reviews, 2016, 35, 427-437.	2.7	82
12	Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. European Journal of Cancer, 2016, 68, 176-178.	1.3	2
13	Acute acalculous cholecystitis due to breast cancer metastasis to the cystic duct. Surgical Case Reports, 2016, 2, 111.	0.2	6
14	Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 1590-1591.	13.9	7
16	Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Current Opinion in Oncology, 2016, 28, 461-468.	1.1	4
17	Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. Clinical Obstetrics and Gynecology, 2016, 59, 756-771.	0.6	2
18	Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. New England Journal of Medicine, 2016, 375, 274-275.	13.9	2
19	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70ÂYears or Older with Hormone Receptor-Positive Breast Cancer?. Annals of Surgical Oncology, 2017, 24, 614-617.	0.7	35
20	Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 111, 66-80.	2.0	49

#	Article	IF	Citations
21	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	0.8	318
22	Extended adjuvant endocrine therapy â€“ A standard to all or some?. Breast, 2017, 32, 112-118.	0.9	12
23	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. Bone, 2017, 97, 147-152.	1.4	33
24	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptorâ€“Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology, 2017, 35, 1041-1048.	0.8	87
25	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 4.	1.3	17
26	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. Expert Review of Anticancer Therapy, 2017, 17, 297-310.	1.1	3
27	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European Journal of Cancer, 2017, 75, 284-298.	1.3	363
28	Weight changes in postmenopausal breast cancer survivors over 2Âyears of endocrine therapy: a retrospective chart review. Breast Cancer Research and Treatment, 2017, 162, 375-388.	1.1	16
29	Extended Endocrine Therapy: Is 5ÂYears Enough?. Current Oncology Reports, 2017, 19, 16.	1.8	5
30	Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 2017, 163, 311-319.	1.1	20
31	MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a caseâ€“control study. Breast Cancer Research and Treatment, 2017, 162, 559-569.	1.1	32
32	A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy. Journal of Cancer Survivorship, 2017, 11, 477-485.	1.5	32
33	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, 2017, 7, 1-12.	1.0	181
34	Surveillance Mammography in Older Patients With Breast Cancerâ€”Can We Ever Stop?. JAMA Oncology, 2017, 3, 402.	3.4	27
35	Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials. Medical Oncology, 2017, 34, 131.	1.2	14
36	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
37	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. Npj Breast Cancer, 2017, 3, 20.	2.3	33
38	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics, 2017, 18, 821-830.	0.6	12

#	Article	IF	Citations
39	Breast Cancer Detected at Screening US: Survival Rates and Clinical-Pathologic and Imaging Factors Associated with Recurrence. Radiology, 2017, 284, 354-364.	3.6	28
40	Family-building After Breast Cancer: Considering the Effect on Adherence to Adjuvant Endocrine Therapy. Clinical Breast Cancer, 2017, 17, 165-170.	1.1	12
41	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer. JAMA Oncology, 2017, 3, 391.	3.4	22
42	Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Annals of Oncology, 2017, 28, 487-496.	0.6	141
43	Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treatment Reviews, 2017, 52, 82-90.	3.4	34
44	Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women. Current Breast Cancer Reports, 2017, 9, 236-241.	0.5	4
45	Recurrence dynamics of breast cancer according to baseline body mass index. European Journal of Cancer, 2017, 87, 10-20.	1.3	35
46	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1502-1511.	5.1	119
47	Extended adjuvant therapy: the role of subset analyses. Lancet Oncology, The, 2017, 18, 1431-1433.	5.1	0
48	Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy. Endocrine-Related Cancer, 2017, 24, C21-C29.	1.6	3
49	A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes. Clinical Cancer Research, 2017, 23, 7217-7224.	3.2	27
50	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 60, 53-59.	3.4	21
51	Longâ€term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata. Journal of Obstetrics and Gynaecology Research, 2017, 43, 1489-1492.	0.6	6
52	De-escalating and escalating systemic therapy of early breast cancer. Breast, 2017, 34, S5-S9.	0.9	3
53	Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer. Breast, 2017, 35, 162-168.	0.9	2
54	Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1357-1362.	0.9	5
55	Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer. Current Breast Cancer Reports, 2017, 9, 183-187.	0.5	1
56	Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1015-1021.	2.3	9

#	Article	IF	Citations
57	Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Research and Treatment, 2017, 166, 657-668.	1.1	62
58	Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. Breast Care, 2017, 12, 146-151.	0.8	8
59	Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer. Breast Care, 2017, 12, 138-144.	0.8	2
60	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment, 2017, 166, 541-547.	1.1	32
61	Hormonal Changes and Sexual Dysfunction. Medical Clinics of North America, 2017, 101, 1135-1150.	1.1	6
62	Comparison of distress in breast cancer survivors treated with different adjuvant endocrine therapies: a single-centre cross-sectional study. Journal of Theoretical Social Psychology, 2017, 27, 271-277.	1.2	4
63	Predicting Nodal Positivity in Women 70ÂYears of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. Annals of Surgical Oncology, 2017, 24, 2881-2888.	0.7	52
64	Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. Future Oncology, 2017, 13, 2733-2736.	1.1	1
65	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	13.9	1,052
66	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 557-568.		0
67	Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety, 2017, 16, 1021-1038.	1.0	58
68	Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment. Breast Cancer Research and Treatment, 2017, 166, 1-13.	1.1	7
69	Preventing invasive breast cancer using endocrine therapy. Breast, 2017, 34, S47-S54.	0.9	14
70	Breast cancer milestones 2007â€“2016. Memo - Magazine of European Medical Oncology, 2017, 10, 27-32.	0.3	0
71	Highlights of the San Antonio Breast Cancer Symposium 2016. Future Oncology, 2017, 13, 1291-1295.	1.1	0
72	Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study. Menopause, 2017, 24, 774-782.	0.8	17
73	Vaginal Estrogens and Aromatase Inhibitors. JAMA Oncology, 2017, 3, 305.	3.4	4
74	A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. JAMA Oncology, 2017, 3, 735.	3.4	0

#	Article	IF	Citations
75	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clinical Breast Cancer, 2017, 17, 11-17.	1.1	60
76	Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. JAMA Oncology, 2017, 3, 163.	3.4	4
77	Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncology, 2017, 3, 186.	3.4	28
78	Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. Breast, 2017, 31, 173-180.	0.9	4
79	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. Therapeutic Advances in Medical Oncology, 2017, 9, 679-692.	1.4	10
82	Letrozole-induced hepatitis with autoimmune features: a rare adverse drug reaction with review of the relevant literature. Oxford Medical Case Reports, 2017, 2017, omx074.	0.2	10
83	Hormone Therapy in Breast Cancer: Where do We Stand?. Journal of Brain Tumors & Neurooncology, 2017, 06, .	0.1	0
84	ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. OncoTargets and Therapy, 2017, Volume 10, 4859-4867.	1.0	11
85	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. Journal of Gynecologic Oncology, 2017, 28, e45.	1.0	24
86	Transcription Factors in Breast Cancerâ€"Lessons From Recent Genomic Analyses and Therapeutic Implications. Advances in Protein Chemistry and Structural Biology, 2017, 107, 223-273.	1.0	14
87	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Frontiers in Oncology, 2017, 7, 26.	1.3	79
89	Endocrine Therapy in Older Women with Early-Stage Hormone Sensitive Breast Cancer. Journal of Gerontology & Geriatric Research, 2017, 06, .	0.1	0
90	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology, 2017, 28, 1700-1712.	0.6	844
91	CYP19A1 gene polymorphism and colorectal cancer etiology in Saudi population: case–control study. OncoTargets and Therapy, 2017, Volume 10, 4559-4567.	1.0	5
92	Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. Journal of Oncology Practice, 2017, 13, e505-e515.	2.5	12
93	Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention. Journal of Clinical Oncology, 2017, 35, 702-704.	0.8	5
94	Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 2017, 35, 2507-2514.	0.8	22
95	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 106-115.	1.8	6

#	Article	IF	Citations
96	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	0.8	14
97	The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications. Annals of Plastic Surgery, 2018, 80, S348-S351.	0.5	4
98	Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. PharmacoEconomics - Open, 2018, 2, 359-369.	0.9	6
99	Good adherence to adjuvant endocrine therapy in early breast cancer â€“ a population-based study based on the Swedish Prescribed Drug Register. Acta OncolÃ³gica, 2018, 57, 935-940.	0.8	20
100	Representation of obese participants in obesity-related cancer randomized trials. Annals of Oncology, 2018, 29, 1582-1587.	0.6	20
101	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. Journal of Molecular Endocrinology, 2018, 61, T233-T252.	1.1	55
102	Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer. Current Treatment Options in Oncology, 2018, 19, 24.	1.3	25
103	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 2018, 110, 40-48.	3.0	138
104	Update Breast Cancer 2018 (Part 1) â€“ Primary Breast Cancer and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2018, 78, 237-245.	0.8	20
105	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptorâ€“Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	3.4	246
107	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Molecular Cancer Research, 2018, 16, 720-727.	1.5	68
108	Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?. Journal of Cancer Survivorship, 2018, 12, 348-356.	1.5	49
109	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2018, , 765-785.	0.1	0
110	The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Review of Molecular Diagnostics, 2018, 18, 227-243.	1.5	115
111	Adjuvant Endocrine Therapy. Cancer Treatment and Research, 2018, 173, 15-29.	0.2	12
112	Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. Breast Cancer Research and Treatment, 2018, 169, 153-162.	1.1	13
113	Breast Cancer in Low- and Middle-Income Countries. Clinics in Laboratory Medicine, 2018, 38, 161-173.	0.7	58
114	Adjuvant Endocrine Therapy. , 2018, , 736-751.e4.		2

#	Article	IF	Citations
115	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2
116	Adjuvant Endocrine Therapy. , 2018, , 427-438.		0
117	Hormone receptor positive breast cancer: state of the art. Current Opinion in Obstetrics and Gynecology, 2018, 30, 51-54.	0.9	12
118	Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Research and Treatment, 2018, 168, 523-530.	1.1	12
119	Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer. Clinical Oncology, 2018, 30, e9-e15.	0.6	22
120	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Research and Treatment, 2018, 168, 169-178.	1.1	3
121	Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. Journal of Cancer Survivorship, 2018, 12, 268-275.	1.5	9
122	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. Journal of the National Cancer Institute, 2018, 110, 6-8.	3.0	5
123	Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. Current Treatment Options in Oncology, 2018, 19, 26.	1.3	44
124	Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 48.	0.4	3
125	Mitochondria Remodeling in Cancer. , 2018, , 153-191.		0
126	The challenges of modeling hormone receptor-positive breast cancer in mice. Endocrine-Related Cancer, 2018, 25, R319-R330.	1.6	33
127	Current Issues in the Overdiagnosis and Overtreatment of Breast Cancer. American Journal of Roentgenology, 2018, 210, 285-291.	1.0	41
128	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 31-39.	3.0	129
129	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. Breast Cancer Research and Treatment, 2018, 167, 235-248.	1.1	8
130	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	1.6	21
131	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	5.1	91
132	Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. Journal of the National Cancer Institute, 2018, 110, 3-5.	3.0	3

#	Article	IF	Citations
133	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. Oncotarget, 2018, 9, 8810-8822.	0.8	15
134	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptorâ€"Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. Journal of Clinical Oncology, 2018, 36, 1941-1948.	0.8	116
135	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
136	Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. Journal of Clinical Oncology, 2018, 36, 563-571.	0.8	19
137	What Is the Role of Symptom Management and Patient-Reported Outcomes in Adherence to Aromatase Inhibitors?. Journal of Clinical Oncology, 2018, 36, 308-309.	0.8	4
138	Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. Gland Surgery, 2018, 7, 449-457.	0.5	10
140	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. New England Journal of Medicine, 2018, 379, 1946-1953.	13.9	4
141	Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. Current Breast Cancer Reports, 2018, 10, 241-250.	0.5	10
142	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2018, 20, 149.	2.2	11
143	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncology and Therapy, 2018, 6, 141-156.	1.0	30
144	Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?. JNCI Cancer Spectrum, 2018, 2, pky035.	1.4	11
145	Lymph node metastasis and high serum CEA areï¿½important prognostic factors in hormone receptor positive and HER2 negative breast cancer. Molecular and Clinical Oncology, 2018, 9, 566-574.	0.4	6
146	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, 2018, 29, 2334-2340.	0.6	97
147	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 2018, 18, 1027.	1.1	3
148	Clinical outcomes comparison of 10Âyears versus 5Âyears of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer, 2018, 18, 977.	1.1	19
150	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1332-1341.	1.1	28
151	Bone health evaluation one year after aromatase inhibitors completion. Bone, 2018, 117, 54-59.	1.4	9
152	Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 1101-1112.	1.1	70

#	Article	IF	Citations
153	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treatment Reviews, 2018, 70, 138-143.	3.4	9
154	Fulvestrant in management of hormone receptor-positive metastatic breast cancer. Future Oncology, 2018, 14, 1789-1800.	1.1	1
155	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. JAMA Oncology, 2018, 4, e181212.	3.4	62
156	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause, 2018, 25, 596-608.	0.8	143
157	Overview of Breast Cancer Therapy. PET Clinics, 2018, 13, 339-354.	1.5	279
158	Longâ€term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5â€year adjuvant treatment in postmenopausal women with earlyâ€stage breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e238-e242.	0.7	3
159	A rude awakening from tumour cells. Nature, 2018, 554, 35-36.	13.7	7
160	Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Research and Treatment, 2018, 172, 167-177.	1.1	33
161	Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. Clinical Breast Cancer, 2018, 18, e1353-e1360.	1.1	7
162	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptorâ€"Positive Breast Cancer. JAMA Oncology, 2018, 4, 1700.	3.4	151
163	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877743.	1.4	12
164	Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data. Journal of Clinical Medicine, 2018, 7, 133.	1.0	24
165	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 167.	3.8	202
166	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Womenâ€™s Health. Endocrinology, 2018, 159, 2980-2990.	1.4	17
167	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Research and Treatment, 2018, 171, 121-129.	1.1	17
168	Assessment and management of bone health in women with oestrogen receptorâ€positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clinical Endocrinology, 2018, 89, 280-296.	1.2	24
169	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research, 2018, 20, 23.	2.2	24
170	Endocrine Therapy for Breast Cancer in the Primary Care Setting. Current Oncology, 2018, 25, 285-291.	0.9	40

#	Article	IF	Citations
171	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. Cancer Treatment Reviews, 2018, 70, 118-126.	3.4	13
172	Cancer Treatmentâ€"Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. Journal of the Endocrine Society, 2018, 2, 574-588.	0.1	21
174	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. Oncologist, 2019, 24, 1432-1438.	1.9	10
175	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
176	Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?. International Urogynecology Journal, 2019, 30, 1879-1886.	0.7	5
177	Assessment and management of bone health in women with oestrogen receptorâ€positive breast cancer receiving endocrine therapy: position statement summary. Medical Journal of Australia, 2019, 211, 224-229.	0.8	11
180	Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. International Journal of Radiation Oncology Biology Physics, 2019, 105, 296-306.	0.4	37
181	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management, 2019, 8, BMT22.	0.2	8
182	Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptorâ€"Positive Early Breast Cancer. Journal of the Endocrine Society, 2019, 3, 1283-1301.	0.1	21
183	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology, 2019, 37, 3425-3435.	0.8	51
184	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. Journal of Breast Cancer, 2019, 22, 387.	0.8	3
185	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€"Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	1.4	15
186	Dermatologic conditions in women receiving systemic cancer therapy. International Journal of Women's Dermatology, 2019, 5, 285-307.	1.1	19
187	Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research. Cancer, 2019, 125, 4452-4461.	2.0	17
188	Leukocytoclastic vasculitis associated with use of aromatase inhibitors. Internal Medicine Journal, 2019, 49, 1162-1167.	0.5	4
189	Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. Acta OncolÃ³gica, 2019, 58, 1581-1593.	0.8	2
190	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 3152-3165.	0.8	117
191	The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. Clinical Breast Cancer, 2019, 19, e731-e740.	1.1	18

#	Article	IF	Citations
192	Evaluating triptorelin as a treatment option for breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 1809-1818.	0.9	3
193	Breast cancer. Nature Reviews Disease Primers, 2019, 5, 66.	18.1	1,620
194	Breast Cancer Treatment. JAMA - Journal of the American Medical Association, 2019, 321, 288.	3.8	2,785
195	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Research and Treatment, 2019, 174, 785-794.	1.1	50
196	Extended adjuvant therapy for earlyâ€stage breast cancer: Are there markers for its use?. Breast Journal, 2019, 25, 7-8.	0.4	0
197	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews, 2019, 74, 29-34.	3.4	23
199	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of Oncology, 2019, 30, 567-574.	0.6	19
200	Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review. Cancer Nursing, 2019, 42, E19-E30.	0.7	21
201	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial â€“ ANZGOG 0903. Gynecologic Oncology, 2019, 154, 29-37.	0.6	35
202	Adjuvant Systemic Therapy in Breast Cancer. , 2019, , 179-194.		0
203	The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database. Breast Journal, 2019, 25, 838-847.	0.4	16
204	Management of Breast Cancer in Older Women. , 2019, , .		0
205	Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up. Journal of Clinical Oncology, 2019, 37, 1515-1516.	0.8	1
206	Efficacy of extended aromatase inhibitors for hormone-receptorâ€“positive breast cancer: A literature-based meta-analysis of randomized trials. Breast, 2019, 46, 19-24.	0.9	16
207	Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials. Clinical Breast Cancer, 2019, 19, e578-e588.	1.1	4
208	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. International Journal of Cancer, 2019, 145, 2114-2121.	2.3	6
209	Bone health in women with breast cancer. Climacteric, 2019, 22, 589-595.	1.1	9
210	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. EBioMedicine, 2019, 42, 352-362.	2.7	35

#	Article	IF	Citations
211	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 2019, 120, 959-967.	2.9	5
212	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€"Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	0.8	384
213	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptorâ€"Positive Breast Cancer: Clinical Versus Molecular Tools. Journal of Clinical Oncology, 2019, 37, 1365-1369.	0.8	17
214	Locally advanced breast cancer in Brazil: current status and future perspectives. Ecancermedicalscience, 2019, 13, 895.	0.6	7
216	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	2.2	10
217	Understanding the unmet sexual health needs of women with breast cancer. Menopause, 2019, 26, 811-813.	0.8	1
219	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. Breast, 2019, 44, 1-14.	0.9	42
220	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nature Reviews Clinical Oncology, 2019, 16, 296-311.	12.5	64
221	Unemployment following breast cancer diagnosis: A population-based study. Breast, 2019, 44, 24-28.	0.9	16
222	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). Contemporary Clinical Trials, 2019, 76, 120-131.	0.8	12
223	Cancer Policy: Pharmaceutical Safety. Cancer Treatment and Research, 2019, , .	0.2	0
224	Cancer Drug Toxicity: Moving from Patient to Survivor. Cancer Treatment and Research, 2019, 171, 107-118.	0.2	3
225	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 The, 2019, 20, 88-99.	5.1	108
226	Competing risks of extended adjuvant aromatase inhibitors. Lancet Oncology, The, 2019, 20, 8-9.	5.1	3
227	Decision Pathways in Breast Cancer Management. , 2019, , 3-97.		0
228	Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. Journal of the National Cancer Institute, 2019, 111, 498-508.	3.0	65
229	Breast cancer metastasis to gynaecological organs: a clinicoâ€pathological and molecular profiling study. Journal of Pathology: Clinical Research, 2019, 5, 25-39.	1.3	31
230	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast Cancer Research and Treatment, 2020, 179, 217-227.	1.1	16

#	Article	IF	Citations
231	Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Research and Treatment, 2020, 179, 275-285.	1.1	26
233	Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormoneâ€positive breast cancer. Breast Journal, 2020, 26, 133-138.	0.4	18
234	CDK4/6 inhibitors in breast cancer â€“ frominÂvitromodels to clinical trials. Acta OncolÃ³gica, 2020, 59, 219-232.	0.8	8
235	Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis. Biological Research for Nursing, 2020, 22, 263-276.	1.0	5
236	Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers. Trends in Endocrinology and Metabolism, 2020, 31, 256-268.	3.1	15
237	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Cancer, 2020, 126, 958-970.	2.0	11
238	Window of opportunity treatment in breast cancer. ANZ Journal of Surgery, 2020, 90, 34-40.	0.3	2
239	Landmark trials in the medical oncology management of early stage breast cancer. Seminars in Oncology, 2020, 47, 278-292.	0.8	6
240	Clinical utility of routine parathyroid hormone measurement in women commenced on endocrine therapy for hormone sensitive breast cancer. Annals of Breast Surgery, 2020, 4, 14-14.	0.8	0
241	A Short-Term Effect of Wearable Technology-Based Lifestyle Intervention on Body Composition in Stage Iâ€“III Postoperative Breast Cancer Survivors. Frontiers in Oncology, 2020, 10, 563566.	1.3	3
242	How to treat lobular cancer in the adjuvant setting?. Current Opinion in Oncology, 2020, 32, 561-567.	1.1	5
243	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. Current Oncology Reports, 2020, 22, 123.	1.8	6
244	Management of hormone receptor-positive, HER2-negative early breast cancer. Seminars in Oncology, 2020, 47, 187-200.	0.8	24
245	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology, 2020, 31, 1359-1365.	0.6	5
246	Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety. Breast Cancer Research and Treatment, 2020, 184, 301-310.	1.1	5
247	New Insights into Therapy-Induced Progression of Cancer. International Journal of Molecular Sciences, 2020, 21, 7872.	1.8	14
248	Validation of Clinical Treatment Score post-5Âyears (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index. Scientific Reports, 2020, 10, 16850.	1.6	9
249	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. Breast Cancer Research and Treatment, 2020, 184, 783-795.	1.1	3

#	Article	IF	Citations
251	A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients. Journal of Radiotherapy in Practice, 2020, , 1-14.	0.2	0
252	Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. Breast Cancer Research and Treatment, 2020, 184, 965-975.	1.1	6
253	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open, 2020, 5, e000743.	2.0	7
254	Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer. Current Treatment Options in Oncology, 2020, 21, 84.	1.3	3
255	Systemic Therapy for Estrogen Receptorâ€"Positive, HER2-Negative Breast Cancer. New England Journal of Medicine, 2020, 383, 2557-2570.	13.9	146
256	Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report. Gynecologic Oncology Reports, 2020, 34, 100634.	0.3	1
257	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Medicine, 2020, 9, 5035-5050.	1.3	8
258	Breast cancer: are long-term and intermittent endocrine therapies equally effective?. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2041-2049.	1.2	7
259	Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. Breast Cancer Research and Treatment, 2020, 182, 355-365.	1.1	15
260	High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast Cancer Research and Treatment, 2020, 183, 41-48.	1.1	7
261	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. Breast Cancer Research and Treatment, 2020, 182, 259-266.	1.1	0
262	Osteoporosis epidemiology using international cohorts. Current Opinion in Rheumatology, 2020, 32, 387-393.	2.0	18
263	The maintenance effect of acupuncture on the side effects of breast cancer endocrine therapy. Medicine (United States), 2020, 99, e20567.	0.4	0
264	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. Chinese Clinical Oncology, 2020, 9, 33-33.	0.4	7
265	Adjuvant and neoadjuvant therapy for breast cancer. Japanese Journal of Clinical Oncology, 2020, 50, 225-229.	0.6	96
266	Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness. Cancer Medicine, 2020, 9, 3551-3562.	1.3	8
267	Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value. Scientific Reports, 2020, 10, 4660.	1.6	10
268	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 2556-2564.	3.2	109

#	Article	IF	Citations
269	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patientsâ€"Part I: Early-Stage Disease. Drugs and Aging, 2020, 37, 331-348.	1.3	3
270	Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. New England Journal of Medicine, 2020, 382, 856-864.	13.9	1
271	Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer. Circulation, 2020, 141, 549-559.	1.6	83
272	Extended endocrine therapy in early breast cancer: how long and who for?. Future Oncology, 2020, 16, 4327-4336.	1.1	5
273	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. Journal of Geriatric Oncology, 2020, 11, 369-379.	0.5	20
275	Survivors of primary breast cancer 5Âyears after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study. Archives of Gynecology and Obstetrics, 2020, 301, 761-767.	0.8	5
276	Healthcare system distrust and the breast cancer continuum of care. Breast Cancer Research and Treatment, 2020, 180, 33-44.	1.1	30
277	The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer, 2021, 28, 67-74.	1.3	5
278	Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research, 2021, 29, 1-12.	4.4	20
279	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptorâ€"positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
280	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2021, 186, 115-123.	1.1	12
281	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clinical Cancer Research, 2021, 27, 311-319.	3.2	58
282	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment, 2021, 185, 205-214.	1.1	19
283	Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors. Supportive Care in Cancer, 2021, 29, 2385-2394.	1.0	10
284	Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis. Translational Breast Cancer Research, 0, 3, 8-8.	0.4	1
285	The role of complementary and alternative methods in the treatment of pain in patients with cancer â€" current evidence and clinical practice: a narrative review. Wspolczesna Onkologia, 2021, 25, 88-94.	0.7	4
286	Impact of breast cancer and its treatment on bone loss and fracture riskâ€"pathophysiology and management. , 2021, , 1395-1406.		0
287	Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. Breast Cancer, 2021, 28, 630-643.	1.3	8

#	Article	IF	Citations
288	Association of Axillary Lymph Node Evaluation With Survival in Women Aged 70 Years or Older With Breast Cancer. Frontiers in Oncology, 2020, 10, 596545.	1.3	3
289	A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting. Journal of Cancer Survivorship, 2023, 17, 139-149.	1.5	5
290	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes, 2021, 12, 285.	1.0	18
291	Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy. Indian Journal of Surgery, 0, , 1.	0.2	1
292	Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. Breast Cancer Research and Treatment, 2021, 187, 455-465.	1.1	2
293	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology, 2021, 7, 609.	3.4	15
294	Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: Is the risk of treatment worse than the risk of recurrence?. Molecular and Cellular Endocrinology, 2021, 525, 111181.	1.6	4
295	Ultrasound-Based Radiomics Analysis for Predicting Disease-Free Survival of Invasive Breast Cancer. Frontiers in Oncology, 2021, 11, 621993.	1.3	27
296	Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer. Current Chemical Biology, 2021, 15, 69-84.	0.2	1
297	Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells. Frontiers in Oncology, 2021, 11, 659963.	1.3	29
298	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. Npj Breast Cancer, 2021, 7, 66.	2.3	35
299	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis and Therapy, 2021, 25, 409-424.	1.6	33
300	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer, 2021, 149, 117-127.	1.3	7
302	Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer. Journal of Clinical Oncology, 2021, 39, 1506-1507.	0.8	0
303	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e47-e61.	1.8	12
304	Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?. Journal of the National Cancer Institute, 2021, 113, 1444-1446.	3.0	1
305	Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Womenâ€™s Decision Making in an Online Breast Cancer Forum. Healthcare (Switzerland), 2021, 9, 688.	1.0	4
306	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, 148, 55-61.	1.0	35

#	Article	IF	Citations
307	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. New England Journal of Medicine, 2021, 385, 395-405.	13.9	82
308	Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Frontiers in Endocrinology, 2021, 12, 713700.	1.5	27
309	De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer. Annals of Surgery, 2021, 274, 654-663.	2.1	11
310	Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. Molecular and Cellular Endocrinology, 2021, 531, 111321.	1.6	10
311	Hormonoterapia adyuvante en cÃ¡ncer de mama. RevisiÃ³n de la Evidencia y Abordaje TerapÃ©utico en el Instituto Instituto Nacional de CancerologÃa, BogotÃ¡, Colombia. Revista Colombiana De CancerologÃa, 0, 25, 130-141.	0.0	0
312	Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. JCO Oncology Practice, 2021, 17, e1055-e1074.	1.4	3
313	Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapyâ€"Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort. Nutrients, 2021, 13, 2902.	1.7	6
314	A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders. Toxicology and Applied Pharmacology, 2021, 425, 115600.	1.3	1
315	Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer. Clinical Breast Cancer, 2021, , .	1.1	2
316	Extended adjuvant aromatase inhibitor therapy: less is more. Med, 2021, 2, 996-998.	2.2	0
317	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. Patient Preference and Adherence, 2021, Volume 15, 2051-2061.	0.8	11
318	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. Science Advances, 2021, 7, eabc8145.	4.7	10
319	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1458-1467.	5.1	41
320	Second invasive breast cancers in patients treated with breast-conserving therapy. European Journal of Surgical Oncology, 2021, 47, 2492-2498.	0.5	5
321	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology, 2021, 32, 1256-1266.	0.6	16
322	Systemic therapy for older patients with early breast cancer. Cancer Treatment Reviews, 2021, 100, 102292.	3.4	5
323	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. Breast Cancer Research, 2021, 23, 1.	2.2	43
324	The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer, 2021, 21, 78.	1.1	23

#	Article	IF	Citations
325	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. Cancers, 2021, 13, 465.	1.7	7
326	Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer. Touch Reviews in Oncology & Haematology, 2021, 17, 12.	0.1	0
327	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	0.6	22
328	Endocrine Therapy in Clinical Practice. Cancer Drug Discovery and Development, 2019, , 215-240.	0.2	1
329	Onkologika. , 2016, , 583-619.		1
330	Onkologika. , 2017, , 597-639.		1
331	Do we still need breast cancer screening in the era of targeted therapies and precision medicine?. Insights Into Imaging, 2020, 11, 105.	1.6	31
332	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program â€œCASCADEâ€• PLoS Medicine, 2016, 13, e1002204.	3.9	119
333	Comparative Study for Clinical Outcomes of Triple-Positive and Triple-Negative Breast Cancer: Long-term Results in 161 Patients Followed in a Single Center. Journal of Breast Disease, 2020, 8, 78-84.	0.2	3
334	The effects of adjuvant endocrine therapy on bone health in women with breast cancer. Journal of Endocrinology, 2019, 241, R111-R124.	1.2	26
335	Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget, 2017, 8, 8406-8419.	0.8	31
336	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
337	Estrogen Receptor Î± (ERÎ±)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity. Current Topics in Medicinal Chemistry, 2019, 19, 1318-1337.	1.0	8
338	Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis. Journal of Korean Medical Science, 2020, 35, e403.	1.1	12
339	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 2019, 30, e86.	1.0	18
340	Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death. Journal of Breast Cancer, 2019, 22, 96.	0.8	11
341	Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan. Tzu Chi Medical Journal, 2020, 32, 175.	0.4	4
342	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice, 2022, 18, 211-216.	1.4	10

#	Article	IF	Citations
343	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of Oncology, 2021, 32, 1571-1581.	0.6	225
344	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patientâ€reported outcomes substudy. Cancer, 2021, , .	2.0	3
345	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0
346	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	0
347	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
348	Invasive Carcinomas. , 2018, , 191-232.		1
349	News in hormonal therapy for breast cancer. Onkologie (Czech Republic), 2017, 11, 257-262.	0.0	0
350	Menopause Symptoms. , 2018, , 277-299.		1
351	Onkologika. , 2018, , 645-691.		1
352	Adjuvant Endocrine Therapy for Breast Cancer. , 2019, , 413-432.		0
353	Onkologika. , 2019, , 817-875.		0
354	Adjuvant Systemic Therapy: Endocrine Therapy. , 2019, , 103-127.		0
355	Adjuvant Hormone Therapy for Breast Cancer. , 2019, , 479-487.		0
356	Bone Health in Patients with Breast Cancer. Oncology & Hematology Review, 2019, 15, 16.	0.2	1
357	Estrogen receptor positive early breast cancer: the long road. Annals of Breast Surgery, 0, 3, 7-7.	0.8	0
358	EvaluaciÃ³n Y Manejo De La Enfermedad Temprana Y Localmente Avanzada: 1er Consenso Nacional Del CÃ¡ncer De Mama de la Sociedad PanameÃ±a de OncologÃa (SPO). Revista Medica De Panama, 2019, 39, .	0.0	0
359	Onkologika. , 2020, , 671-732.		2
361	Is the extension of adjuvant hormone therapy for breast cancer justified?. Meditsinskiy Sovet, 2020, , 74-79.	0.1	0

#	Article	IF	Citations
362	Surgical Cases of Pulmonary Nodules in Patients with Breast Cancer. Japanese Journal of Lung Cancer, 2021, 61, 389-395.	0.0	0
363	Early Recurrence of Breast Cancer after the Primary Treatment: Analysis of Clinicopathological and Radiological Predictive Factors. Journal of the Korean Society of Radiology, 2020, 81, 395.	0.1	0
364	Adjuvante Therapie des Mammakarzinoms. , 2020, , 403-419.		0
365	Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. , 2020, , 217-236.		0
366	Precautions for Patients Taking Aromatase Inhibitors. Journal of the Advanced Practitioner in Oncology, 2020, 11, 184-189.	0.2	1
367	Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers. Frontiers in Oncology, 2021, 11, 660318.	1.3	8
368	The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience. Cancers, 2021, 13, 5539.	1.7	7
369	Adjuvant Endocrine Therapy in Early Breast Cancer. , 2021, , 165-177.		0
370	Digestive Disease Week And American Society of Clinical Oncology. P and T, 2016, 41, 446-51.	1.0	0
371	Endocrine Therapy for Early Breast Cancer: Updated Review. Ochsner Journal, 2017, 17, 405-411.	0.5	44
372	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. Journal of the Advanced Practitioner in Oncology, 2016, 7, 666-671.	0.2	0
373	Genomic Testing in the Management of Early-Stage Breast Cancer. Journal of Clinical Outcomes Management, 2017, 24, 229-238.	1.7	1
374	Mammakarzinom. , 2022, , 340-351.		0
375	Endocrine Treatment for Breast Cancer Patients Revisitedâ€"History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.	1.7	16
376	Predicting the clinical outcomes and benefit from letrozole after 5Âyears of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. Breast Cancer Research and Treatment, 2021, , 1.	1.1	0
377	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm, 2021, 2, 514-530.	3.1	12
379	Is It Time to Consider the Androgen Receptor as a Therapeutic Target in Breast Cancer?. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 775-786.	0.9	7
380	Onkologika. , 2021, , 579-638.		0

#	Article	IF	Citations
381	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptorâ€"Mutated Nonâ€"Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	3.2	14
382	Long-term control of recurrent disease in a patient with hormones receptor-positive breast cancer. , 2021, 1, 56.		0
383	Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients. Cancer Control, 2022, 29, 107327482110689.	0.7	2
384	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 829875.	1.3	19
385	How we treat HR-positive, HER2-negative early breast cancer. Future Oncology, 2022, 18, 1003-1022.	1.1	11
386	Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clinical Cancer Research, 2022, 28, 1871-1880.	3.2	11
387	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptorâ€"Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	3.4	27
388	Abbreviated endocrine therapy duration for low estrogen receptorâ€positive breast cancer: The counter to extended endocrine therapy. Cancer, 2022, , .	2.0	1
389	Feasibility Trial to Evaluate Tendon Stiffness Obtained from Shear Wave Elastography Imaging as a Biomarker of Aromatase Inhibitor-Induced Arthralgias. Journal of Clinical Medicine, 2022, 11, 1067.	1.0	2
390	Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World Journal of Clinical Oncology, 2022, 13, 71-100.	0.9	29
391	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. European Journal of Cancer, 2022, 164, 52-61.	1.3	0
392	Endocrine therapy initiation among women with stage Iâ€"III invasive, hormone receptor-positive breast cancer from 2001â€"2016. Breast Cancer Research and Treatment, 2022, 193, 203-216.	1.1	5
393	Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1321-1328.e3.	0.7	3
394	Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews, 2022, 105, 102375.	3.4	82
395	Alternatives for the prevention of cancer recurrences: immunonutrition, Catâ€™s claw and Rhopalus junceus venom. Journal of the Dow University of Health Sciences, 2021, 15, .	0.2	0
396	Treatment and Survivorship Interventions to Prevent Poor Body Image Outcomes in Breast Cancer Survivors. Breast Cancer: Targets and Therapy, 2021, Volume 13, 701-709.	1.0	5
397	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. Cancer Medicine, 2022, 11, 297-307.	1.3	2
399	Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database. Pharmaceuticals, 2021, 14, 1299.	1.7	5

#	Article	IF	Citations
400	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. Npj Breast Cancer, 2022, 8, 53.	2.3	11
401	Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. Cureus, 2022, , .	0.2	2
402	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Research and Treatment, 2022, , .	1.1	2
403	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. Critical Reviews in Oncology/Hematology, 2022, 175, 103725.	2.0	1
404	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptorâ€"Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 60-72.	1.8	15
405	The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors. Osteoporosis International, 0, , .	1.3	0
406	Preventing late recurrence in hormone receptor-positive early breast cancer: a review. European Journal of Cancer, 2022, 172, 53-64.	1.3	3
407	Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancerâ€"A Literature Review. Current Oncology, 2022, 29, 4956-4969.	0.9	3
408	Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. Frontiers in Psychology, 0, 13, .	1.1	0
410	Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy. British Journal of Cancer, 0, , .	2.9	0
411	Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Research and Treatment, 2022, 196, 143-152.	1.1	4
412	Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptorâ€"Positive Breast Cancer. JAMA Network Open, 2022, 5, e2225485.	2.8	12
413	Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer. Cancer Research, 2022, 82, 3614-3621.	0.4	1
414	Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?. Cancer Treatment Reviews, 2022, 110, 102445.	3.4	8
415	Comparison of Time-Varying Pattern of Recurrence in Chinese Breast Cancer Patients with Different Molecular Subtypes: A Single-Center Retrospective Study. Oncologie, 2022, 24, 451-469.	0.2	0
416	Increased Clinical Pain Locations and Pain Sensitivity in Women after Breast Cancer Surgery. Clinical Journal of Pain, 0, Publish Ahead of Print, .	0.8	3
417	Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3
418	TGF-Î² at the crossroads of multiple prognosis in breast cancer, and beyond. Life Sciences, 2022, 310, 121011.	2.0	2

#	Article	IF	Citations
419	Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy â€“ A Review Study. The Journal of Breast Health, 2022, 18, 292-298.	0.4	1
420	Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study. Breast, 2022, 66, 89-96.	0.9	5
421	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. Frontiers in Oncology, 0, 12, .	1.3	1
422	Adherence to adjuvant hormonal therapy in localised breast cancer. European Journal of Cancer Care, 2022, 31, .	0.7	2
423	Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials. Frontiers in Oncology, 0, 12, .	1.3	4
425	Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests. International Journal of Molecular Sciences, 2022, 23, 13604.	1.8	1
426	Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis. Critical Reviews in Oncology/Hematology, 2023, 181, 103898.	2.0	5
427	The boneâ€“muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. Breast Cancer Research, 2022, 24, .	2.2	3
429	Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis. Breast Cancer, 0, , .	1.3	0
430	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer and Metastasis Reviews, 2023, 42, 161-182.	2.7	10
431	Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptorâ€“positive breast cancer. Frontiers in Oncology, 0, 12, .	1.3	0
432	Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older. International Journal of Radiation Oncology Biology Physics, 2023, 116, 617-626.	0.4	1
433	Diagnostics and management of vulvovaginal atrophy according to the international guidelines. Fundamental and Clinical Medicine, 2022, 7, 110-121.	0.1	0
434	Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology, 2023, 30, 1461-1472.	0.9	12
435	Management of bone loss due to endocrine therapy during cancer treatment. Osteoporosis International, 2023, 34, 671-680.	1.3	3
437	Tailoring Treatment for Patients with Inflammatory Breast Cancer. Current Treatment Options in Oncology, 2023, 24, 580-593.	1.3	8
438	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. Breast Cancer: Targets and Therapy, 0, Volume 15, 251-261.	1.0	0
439	Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?. JNCI Cancer Spectrum, 0, , .	1.4	0

#	Article	IF	Citations
440	Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer. Plastic and Reconstructive Surgery, 0, Publish Ahead of Print, .	0.7	0
441	Prolonged endocrine therapy in the management of hormone <scp>receptorâ€positive earlyâ€stage</scp> breast cancer: What is the appropriate duration?. Journal of Obstetrics and Gynaecology Research, 2023, 49, 1079-1082.	0.6	0
442	HÃmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
443	Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients. Metabolites, 2023, 13, 452.	1.3	0
444	Systemic therapy for hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative early stage and metastatic breast cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 480-515.	157.7	23
446	Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2023, 13, e070972.	0.8	0
447	Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptorâ€"Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology, 2023, 41, 3329-3338.	0.8	7
448	Encapsulation for breast cancer treatment. , 2023, , 661-720.		0
467	Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis. Breast Cancer Research and Treatment, 0, , .	1.1	0
480	Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 0, , .	1.1	0
494	Interventions to improve oral endocrine therapy adherence in breast cancer patients. Journal of Cancer Survivorship, 0, , .	1.5	0
503	HÃmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0